On Tuesday shares of Halliburton Company (NYSE:HAL) closed at $44.52. Company’s sales growth for last 5 years was 17.50% and EPS growth for next 5 years is recorded as 10.68%. Halliburton Company (NYSE:HAL) which is seeking regulatory approval for its roughly $35 billion purchase of Baker Hughes Inc., plans to sell three drilling business. The three businesses are drill bits, directional drilling and its LWD/MWD businesses, which are logging while drilling and measurement while drilling. The divisions will be marketed separately, the oilfield-service company said Tuesday.
CHC Group Ltd. (NYSE:HELI) in last trading activity fell -6.71% to close at $1.39. Company weekly performance is 11.20% while its quarterly performance stands at -51.74%. CHC Group Ltd. (NYSE:HELI) is -85.07% away from its 52 week high. CHC Group Ltd. (NYSE:HELI) announced that its indirect wholly owned subsidiary CHC Helicopter S.A. has commenced a cash tender offer to purchase up to $80 million aggregate principal amount of its outstanding 9.375% Senior Notes due 2021. This amount may be increased at the sole discretion of CHC. If the aggregate principal amount of notes tendered exceeds this amount, the tendered notes will be subject to proration.
On last trading day ABM Industries Incorporated (NYSE:ABM) fell -0.93% to close at $31.82. Its volatility for the week is 1.35% while volatility for the month is 1.93%. ABM’s sales growth for past 5 years was 7.60% and its EPS growth for past 5 years was 4.30%. ABM Industries Incorporated (NYSE:ABM) monthly performance is 8.90%. ABM (NYSE:ABM), announced the appointment of D. Anthony Scaglione as executive vice president and chief financial officer, effective immediately.
Pfizer Inc. (NYSE:PFE) belongs to Healthcare sector. Its net profit margin is 23.10% and weekly performance is -1.31%. On last trading day company shares ended up $34.54. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is 2.03%. German drug maker Merck KGaA and Pfizer Inc. (NYSE:PFE) said they have finalized a co-promotion agreement that will enable the companies to co-promote Pfizer’s anaplastic lymphoma kinase or ALK inhibitor Xalkori (crizotinib).
Cytori Therapeutics, Inc. (NASDAQ:CYTX) shares increased 2.27% in last trading session and ended the day at $1.35. CYTX Gross Margin is 61.80% and its return on assets is -131.80%. Cytori Therapeutics, Inc. (NASDAQ:CYTX) quarterly performance is 170.00%. Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union (EU).